Myocardial infarct expansion and matrix metalloproteinase inhibition

Rupak Mukherjee1, Theresa A Brinsa, Kathryn B Dowdy

  • 1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.

Circulation
|February 5, 2003
PubMed
Abstract

Insights

Matrix metalloproteinase inhibition (MMPi) reduced left ventricular (LV) dilation and infarct expansion after myocardial infarction (MI). MMPi also modulated specific MMP and tissue inhibitor of MMPs (TIMP) levels in the affected heart region.

Area of Science:

  • Cardiovascular Research
  • Cardiac Remodeling
  • Pharmacological Intervention

Background:

  • Left ventricular (LV) remodeling post-myocardial infarction (MI) may involve matrix metalloproteinase (MMP) activation.
  • Investigating MMP inhibition (MMPi) offers a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the impact of MMP inhibition on regional LV geometry following myocardial infarction.
  • To assess changes in MMP and tissue inhibitor of MMPs (TIMP) levels after MI with MMPi.

Main Methods:

  • Utilized pigs with radiopaque markers to measure regional myocardial geometry after inducing MI.
  • Administered MMPi (PD166793) or placebo to pigs post-MI and assessed outcomes over 2 and 8 weeks.
  • Measured LV dimensions, infarct size, MMP activity, and TIMP-1 levels.

Main Results:

  • MMPi significantly attenuated LV end-diastolic dimension and reduced regional infarct area at 8 weeks post-MI compared to the MI-only group.
  • Ex vivo MMP proteolytic activity was reduced by MMPi.
  • MMPi normalized membrane-type MMP levels and increased TIMP-1 levels in the MI region.

Conclusions:

  • MMP inhibition effectively attenuated LV dilation and infarct expansion during the late phase of MI healing.
  • Exogenous MMPi demonstrated region-specific modulation of MMPs and TIMPs.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...